Lacktman Comments on Proposed 2019 Medicare Physician Fee Schedule and Quality Payment Program
20 July 2018
Partner Nate Lacktman was quoted in an mHealthIntelligence article, “CMS Makes a ‘Landmark Change’ in RPM, Telehealth Reimbursement,” about proposed changes in the 2019 Medicare Physician Fee Schedule and Quality Payment Program that are designed to boost remote patient monitoring and telehealth programs.
Lacktman said the Centers for Medicare & Medicaid Services has introduced three proposed new remote patient monitoring codes (RPM) that are intended to better reflect how RPM services can be delivered to patients. Under the new codes, he said, less treatment time would be required to qualify for reimbursement, separate reimbursement would be offered for the time spent setting up the RPM equipment and for educating the patient on its use, and clinical staff would be allowed to perform RPM services.
Lacktman said the Centers for Medicare & Medicaid Services has introduced three proposed new remote patient monitoring codes (RPM) that are intended to better reflect how RPM services can be delivered to patients. Under the new codes, he said, less treatment time would be required to qualify for reimbursement, separate reimbursement would be offered for the time spent setting up the RPM equipment and for educating the patient on its use, and clinical staff would be allowed to perform RPM services.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”